Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus rating of “Buy” from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $23.71.

ZVRA has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a “buy” rating and a $26.00 target price on the stock. Cantor Fitzgerald lifted their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Thursday, July 10th. Wall Street Zen upgraded Zevra Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $12.79 on Tuesday. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46. The stock’s fifty day simple moving average is $9.06 and its two-hundred day simple moving average is $8.20. Zevra Therapeutics has a 1-year low of $5.45 and a 1-year high of $12.90. The stock has a market cap of $699.36 million, a PE ratio of -6.73 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to analysts’ expectations of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same period last year, the business earned ($0.40) EPS. As a group, analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ZVRA. Woodline Partners LP boosted its position in shares of Zevra Therapeutics by 11.5% during the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock valued at $34,571,000 after acquiring an additional 476,032 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock worth $30,441,000 after buying an additional 3,001,000 shares during the last quarter. Vanguard Group Inc. lifted its position in Zevra Therapeutics by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock worth $23,554,000 after buying an additional 68,151 shares during the last quarter. Altium Capital Management LLC lifted its position in Zevra Therapeutics by 8.8% in the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock worth $15,429,000 after buying an additional 150,000 shares during the last quarter. Finally, AIGH Capital Management LLC lifted its position in Zevra Therapeutics by 82.4% in the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after buying an additional 649,495 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.